Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 758 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Post-Viral Disorder (Disorder) Clear all

Conditions: Long COVID, Long Covid19
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Fever After Vaccination, Fever, Febrile Seizure
Interventions: PCV13, DTaP, IIV; Biological
Lead sponsor: Duke University; Other
Eligibility: 12 Months to 16 Months
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Oakland, California • Atlanta, Georgia • Durham, North Carolina

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 vaccine, Control; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 9 Years to 49 Years · Female only
Enrollment: 3,855 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more

Conditions: HIV Infections
Interventions: Tenofovir disoproxil; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Minneapolis, Minnesota

Conditions: Long COVID, Cardiorespiratory Fitness
Interventions: 140 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK), 210 ml of nitrate-depleted placebo; Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Hepatitis B
Interventions: Prednisone Priming; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: COVID-19, Long Haul
Interventions: Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach; Drug · Diagnostic Test · Biological + 3 more
Lead sponsor: Well- Konnect Healthcare Services and Research Firm; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation, Herpes Zoster (HZ)
Interventions: Shingrix; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 4
States / cities: Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 1 more

Conditions: Herpes Zoster, Post-herpetic Neuralgia
Interventions: Gabapentin, Valacyclovir; Drug
Lead sponsor: Center for Clinical Studies, Texas; Other
Eligibility: 50 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Long COVID-19 Syndrome
Interventions: Low carbohydrate diet intervention; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Covid19
Interventions: Not listed
Lead sponsor: Tulane University; Other
Eligibility: 6 Months to 120 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Transplantation Infection
Interventions: Cidofovir, No Cidofovir; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 6 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C Virus Infection
Interventions: ABT-072; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia, MDS (Myelodysplastic Syndrome), Relapsed Non-Hodgkin Lymphoma, Acquired Aplastic Anemia, Inherited BMF Syndrome, Immunodeficiency, Primary Immune Regulatory Disorder, Hemoglobinopathies, Bone Marrow Failure, Inborn Errors of Metabolism, HLH
Interventions: Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3, Phase 2 Maximum Tolerated Dose determined in Phase 1, Phase 2 Established Dose from prior study, NCT03810196; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Efgartigimod, Placebo; Drug
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: La Jolla, California • Palo Alto, California • Glenview, Illinois + 8 more

Conditions: COVID-19, Post Acute Sequelae of COVID-19, Long COVID, Organ Dysfunction Syndrome, Multiple, Frailty Syndrome
Interventions: Blood and nasal swab sampling; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Sylmar, California • Torrance, California + 3 more

Conditions: Cytomegalovirus Infection
Interventions: Maribavir, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 13
States / cities: Duarte, California • Los Angeles, California • Maywood, Illinois + 10 more

Conditions: Long COVID, Distress Tolerance
Interventions: iENDURE; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Post-polio Syndrome, Physical Activity, Depression, Pain, Sleep Disorders
Interventions: Glutathione; Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Diego, California • Denver, Colorado • Atlanta, Georgia

Conditions: Chronic Lymphocytic Leukemia, CML (Chronic Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), Acute Lymphoblastic Leukemia, AML (Acute Myelogenous Leukemia)
Interventions: MVST, MVSTr; Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers, Influenza
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Substance Use Disorder (SUD), HIV (Human Immunodeficiency Virus), Viral Suppression of HIV Infection
Interventions: DEST2nation model, Standard of care referral; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Long Island City, New York • Philadelphia, Pennsylvania

Conditions: Long COVID
Interventions: Fermented foods, Control; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Understanding the Long-term Impact of COVID-19 in Adults

Fever After Simultaneous Versus Sequential Vaccination in Young Children

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Artery Elasticity After Switch From Epzicom to Truvada

Nitrite Supplementation in Long COVID Patients

Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

Shingrix in Renal Transplant Recipients

Reduction of Postherpetic Neuralgia in Herpes Zoster

Long COVID-19 Syndrome Lifestyle Intervention Study

Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development

Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

COVID-19 Outcome Prediction Algorithm

Maribavir for Prevention of CMV After Stem Cell Transplants

Long COVID-19 Intervention Using Digital Health & Technology

Glutathione and Health With Post-Polio Syndrome

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines

Decentralized, Status Neutral, Stakeholder-engaged, Post-incarceration Intervention for People Living With and at Risk for HIV

Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID